| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1bedf26ed145fcc46cdd7f7c6b76653 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14 |
| filingDate |
2019-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b647d18bc049b8fff1764ee45c6b149
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3bbda986f39fe5562a106ddf7ec3b9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f86c11ffe6bf1d09d2bbf0faf8d91c47 |
| publicationDate |
2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022002306-A1 |
| titleOfInvention |
Crystal form of upadacitinib and preparation method and use thereof |
| abstract |
The present disclosure relates to a crystalline form of upadacitinib and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing a JAK inhibitor drug, and use of the crystalline form for preparing drugs treating rheumatoid arthritis. The crystalline form of upadacitinib provided by the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development. |
| priorityDate |
2018-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |